Why the study?
Does treatment at high-PVAD hospitals compared to high-IABP hospitals affect escalation of support and resource utilization in adults with acute myocardial infarction cardiogenic shock?
Cohort (n=53,903)
Yes
Does treatment at high-PVAD hospitals compared to high-IABP hospitals affect escalation of support and resource utilization in adults with acute myocardial infarction cardiogenic shock?
Absolute Event Rate: 18% vs 13%
There is significant interhospital variation in the choice of mechanical circulatory support for AMI cardiogenic shock, with high-PVAD hospitals showing lower rates of escalation to ECMO or LVAD but similar overall resource utilization compared to high-IABP hospitals.
Background Cardiogenic shock (CS) is a leading cause of mortality following acute myocardial infarction (AMI). Some patients may require intra-aortic balloon pump (IABP) or percutaneous ventricular assist device (PVAD) placement; however, there is a paucity of standardised algorithms to guide the deployment of each device. The present study evaluated interhospital variation in the use of IABP and PVAD for AMI CS and identified institutional factors associated with hospital-level device preference. Methods All non-elective adult hospitalisations entailing AMI and CS were identified within the 2019 Nationwide Readmissions Database. Patients were grouped into IABP, PVAD and non-mechanical circulatory support cohorts. The primary aim was to quantify the degree of interhospital variation in the use of IABP and PVAD. Escalation to extracorporeal membrane oxygenation (ECMO), left ventricular assist device (LVAD) implantation, length of stay and hospitalisation costs were secondarily assessed. Hospital factors, such as percutaneous coronary intervention (PCI) volume and safety net status, were also analysed. Results Among 53 903 patients, 23.4% received IABP, and 12.5% received PVAD. After adjustment for patient factors, approximately 13% (11–14%) of variation in IABP use and 18% (15–20%) of PVAD use were attributable to centre-level differences. High-PVAD hospitals had higher annual PCI volume (257 (185–369) vs 204 (148–276) cases/year, p=0.032) and were more commonly safety net institutions (27.4% vs 11.3%, p=0.023), compared to high-IABP hospitals. Patients treated at high-IABP and high-PVAD hospitals faced similar length of stay (β −0.16, 95% CI −1.82 to 1.49) and costs (β −$3500, 95% CI −16 600 to 9600). Those at high-PVAD hospitals had lower adjusted risk of escalation to ECMO (0.52, 95% CI 0.29 to 0.95) and LVAD implantation (0.28, 95% CI 0.08 to 0.94). Conclusions The present study identified wide interhospital variation in the use of IABP and PVAD for AMI CS. Although the likelihood of escalation to ECMO or LVAD differed between hospital types, resource utilisation was similar.
No takes yet. Share an insight, caveat, or question.
Verma et al. (2025) conducted a cohort in Acute myocardial infarction cardiogenic shock (n=53,903). Percutaneous ventricular assist device (PVAD) vs. Intra-aortic balloon pump (IABP) was evaluated on Interhospital variation in device use attributable to centre-level differences.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: